Sentinel lymph node biopsy and neoadjuvant chemotherapy  in the management of early breast cancer: Safety considerations and timing

Edge, Jenny; Nietz, Sarah

doi:10.7196/samj.2017.v107i6.12239

Cited by 2 publications

(2 citation statements)

References 23 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preoperative detection of lymph node metastasis status is of great importance for surgical procedures and patient prognosis, and avoids unnecessary complications caused by extensive lymph node dissection. 6 , 7 Studies have shown that SLN status is usually representative of the pathological status of axillary lymph nodes. For SLN negative breast cancer patients, axillary lymph node dissection (ALND) is not necessary, thereby reducing operative complications and improving the quality of life of breast cancer patients.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis

et al. 2021

View full text Add to dashboard Cite

Background: To investigate the diagnostic efficacy of sentinel lymph nodes (SLN) in breast cancer by percutaneous contrast-enhanced ultrasound (CEUS) through pooled analysis of relevant studies published before June 2021. Methods: We conducted a systematic review and meta-analysis of relevant studies by searching the electronic databases of PubMed, Embase, Cochrane Library, Chinese National Knowledge Infrastructure, Wanfang and VIP and the studies were screened according to their inclusion and exclusion criteria. Sensitivity (SEN), specificity (SPE), positive likelihood ratio (+LR), negative likelihood ratio (ÀLR) and diagnostic odds ratio (DOR) were calculated by Meta-disc 1.4 software and the summary receiver operating characteristic (SROC) curve and area under the curve of ROC (AUC) were constructed.Results: Twenty-two publications evaluating the diagnostic efficacy of SLN in breast cancer under percutaneous CEUS were included in the meta-analysis. The diagnostic sensitivity, specificity were 0.86 (95% CI: 0.83-0.88) and 0.89 (95% CI: 0.87-0.91) for SLN in breast cancer detected by percutaneous CEUS respectively using a random effect model. The +LR and -LR were combined in a random effect model due to significant statistical heterogeneity (p < 0.05). The pooled +LR, ÀLR were 7.06 (95% CI: 4.34-11.50), and 0.17 (95% CI: 0.12-0.24), respectively. The combined DOR was 53.32 (95% CI: 29.74-95.61) for SLN diagnosis in breast cancer by percutaneous CEUS under a random effect model. The AUC was 0.94 which indicated that CEUS had high diagnostic efficacy of SLN in patients with breast cancer. Conclusions: CEUS is a noninvasive method for the detection SLN in patients of breast cancer with relative high prediction efficacy.

show abstract

Section: Introductionmentioning

confidence: 99%

Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The CPGs are generally concordant in respect to the necessity of axillary staging and SLNB (sentinel lymph node biopsy) [ 4 ]. According to ESMO, the SLNB has replaced routine axillary dissection as a standard of care in early BC, for patients with negative node—disease (IIA) [ 18 ]. ESMO guidelines state that no further axillary procedures are required in patients with limited SLNB involvement or presence of isolated tumour cells (< 0,2 mm) in the SLN, who benefit from breast irradiation (IIB) [ 1 ].…”

Section: Breast Cancer Treatmentmentioning

confidence: 99%

Guidance and Standards for Breast Cancer Care in Europe

Wilde

Devassy

Roche

et al. 2020

J Obstet Gynecol India

View full text Add to dashboard Cite

The increasing incidence and mortality rates of breast cancer have led to the necessity of initiating and developing clinical practice guidelines in order to optimize cancer control and provide patients with the best care. These guidelines are either national or issued by reputed relevant European societies—like European Society for Medical Oncology. Many of the recommendations are concordant in-between the guidelines. However, there are still considerable discrepancies to be noted between guidelines from different European countries, which could hinder physicians from implementing their recommendations. The present paper summarizes and compares the recommendations included in the various European guidelines.

show abstract

Sentinel lymph node biopsy and neoadjuvant chemotherapy in the management of early breast cancer: Safety considerations and timing

Cited by 2 publications

References 23 publications

Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis

Diagnostic efficacy of sentinel lymph node in breast cancer under percutaneous contrast‐enhanced ultrasound: An updated meta‐analysis

Guidance and Standards for Breast Cancer Care in Europe

Contact Info

Product

Resources

About